Cost of Revenue Comparison: Viridian Therapeutics, Inc. vs MiMedx Group, Inc.

Biotech Cost Dynamics: Viridian vs. MiMedx

__timestampMiMedx Group, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 2014126650003243000
Thursday, January 1, 2015202020002472000
Friday, January 1, 2016324070002548000
Sunday, January 1, 20173521900019623000
Monday, January 1, 20183638600030421000
Tuesday, January 1, 20194308100032793999
Wednesday, January 1, 20203933000028304000
Friday, January 1, 202143283000620000
Saturday, January 1, 202248316000755000
Sunday, January 1, 2023546340001322000
Loading chart...

Unleashing the power of data

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of biotechnology, understanding cost structures is crucial. This analysis compares the cost of revenue for Viridian Therapeutics, Inc. and MiMedx Group, Inc. over the past decade. From 2014 to 2023, MiMedx Group consistently outpaced Viridian in cost of revenue, peaking at approximately $54.6 million in 2023, a 330% increase from 2014. In contrast, Viridian's costs fluctuated, with a notable spike in 2019 reaching $32.8 million, before dropping significantly in subsequent years. This volatility reflects Viridian's strategic shifts and market challenges. By 2023, their cost of revenue was just $1.3 million, highlighting a dramatic reduction. This comparison underscores the diverse financial strategies and market responses of these two companies, offering insights into their operational efficiencies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025